Literature DB >> 25540368

A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Christine A Bricault1, James M Kovacs2, Joseph P Nkolola1, Karina Yusim3, Elena E Giorgi3, Jennifer L Shields1, James Perry1, Christy L Lavine1, Ann Cheung1, Katharine Ellingson-Strouss4, Cecelia Rademeyer5, Glenda E Gray6, Carolyn Williamson5, Leonidas Stamatatos7, Michael S Seaman1, Bette T Korber3, Bing Chen2, Dan H Barouch8.   

Abstract

UNLABELLED: The sequence diversity of human immunodeficiency virus type 1 (HIV-1) presents a formidable challenge to the generation of an HIV-1 vaccine. One strategy to address such sequence diversity and to improve the magnitude of neutralizing antibodies (NAbs) is to utilize multivalent mixtures of HIV-1 envelope (Env) immunogens. Here we report the generation and characterization of three novel, acute clade C HIV-1 Env gp140 trimers (459C, 405C, and 939C), each with unique antigenic properties. Among the single trimers tested, 459C elicited the most potent NAb responses in vaccinated guinea pigs. We evaluated the immunogenicity of various mixtures of clade C Env trimers and found that a quadrivalent cocktail of clade C trimers elicited a greater magnitude of NAbs against a panel of tier 1A and 1B viruses than any single clade C trimer alone, demonstrating that the mixture had an advantage over all individual components of the cocktail. These data suggest that vaccination with a mixture of clade C Env trimers represents a promising strategy to augment vaccine-elicited NAb responses. IMPORTANCE: It is currently not known how to generate potent NAbs to the diverse circulating HIV-1 Envs by vaccination. One strategy to address this diversity is to utilize mixtures of different soluble HIV-1 envelope proteins. In this study, we generated and characterized three distinct, novel, acute clade C soluble trimers. We vaccinated guinea pigs with single trimers as well as mixtures of trimers, and we found that a mixture of four trimers elicited a greater magnitude of NAbs than any single trimer within the mixture. The results of this study suggest that further development of Env trimer cocktails is warranted.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25540368      PMCID: PMC4325749          DOI: 10.1128/JVI.03331-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.

Authors:  X Yang; R Wyatt; J Sodroski
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  Immunologic correlates of protection induced by vaccination.

Authors:  S A Plotkin
Journal:  Pediatr Infect Dis J       Date:  2001-01       Impact factor: 2.129

3.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

4.  Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer.

Authors:  Joseph P Nkolola; Christine A Bricault; Ann Cheung; Jennifer Shields; James Perry; James M Kovacs; Elena Giorgi; Margot van Winsen; Adrian Apetri; Els C M Brinkman-van der Linden; Bing Chen; Bette Korber; Michael S Seaman; Dan H Barouch
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

5.  Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.

Authors:  M W Cho; Y B Kim; M K Lee; K C Gupta; W Ross; R Plishka; A Buckler-White; T Igarashi; T Theodore; R Byrum; C Kemp; D C Montefiori; M A Martin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

7.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

Review 8.  Diversity considerations in HIV-1 vaccine selection.

Authors:  Brian Gaschen; Jesse Taylor; Karina Yusim; Brian Foley; Feng Gao; Dorothy Lang; Vladimir Novitsky; Barton Haynes; Beatrice H Hahn; Tanmoy Bhattacharya; Bette Korber
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

9.  Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.

Authors:  Devin Sok; Katie J Doores; Bryan Briney; Khoa M Le; Karen L Saye-Francisco; Alejandra Ramos; Daniel W Kulp; Jean-Philippe Julien; Sergey Menis; Lalinda Wickramasinghe; Michael S Seaman; William R Schief; Ian A Wilson; Pascal Poignard; Dennis R Burton
Journal:  Sci Transl Med       Date:  2014-05-14       Impact factor: 17.956

10.  Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Authors:  Anila Yasmeen; Rajesh Ringe; Ronald Derking; Albert Cupo; Jean-Philippe Julien; Dennis R Burton; Andrew B Ward; Ian A Wilson; Rogier W Sanders; John P Moore; Per Johan Klasse
Journal:  Retrovirology       Date:  2014-05-29       Impact factor: 4.602

View more
  25 in total

1.  Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Anila Yasmeen; Gabriel Ozorowski; Eden P Go; Laura K Pritchard; Miklos Guttman; Thomas A Ketas; Christopher A Cottrell; Ian A Wilson; Rogier W Sanders; Albert Cupo; Max Crispin; Kelly K Lee; Heather Desaire; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

Review 2.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

3.  DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant.

Authors:  Veena Menon; Victor I Ayala; Sneha P Rangaswamy; Irene Kalisz; Stephen Whitney; Lindsey Galmin; Asma Ashraf; Celia LaBranche; David Montefiori; Nikolai Petrovsky; Vaniambadi S Kalyanaraman; Ranajit Pal
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

4.  Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.

Authors:  Lindsay Wieczorek; Shelly J Krebs; Vaniambadi Kalyanaraman; Stephen Whitney; Sodsai Tovanabutra; Carlos G Moscoso; Eric Sanders-Buell; Constance Williams; Bonnie Slike; Sebastian Molnar; Vincent Dussupt; S Munir Alam; Agnes-Laurence Chenine; Tina Tong; Edgar L Hill; Hua-Xin Liao; Michael Hoelscher; Leonard Maboko; Susan Zolla-Pazner; Barton F Haynes; Michael Pensiero; Francine McCutchan; Shawyon Malek-Salehi; R Holland Cheng; Merlin L Robb; Thomas VanCott; Nelson L Michael; Mary A Marovich; Carl R Alving; Gary R Matyas; Mangala Rao; Victoria R Polonis
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

Review 5.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

6.  Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.

Authors:  Chen S Tan; Joshua Ghofrani; Emma Geiger; Igor J Koralnik; Stephanie Jost
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

7.  HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.

Authors:  Jia Chen; James M Kovacs; Hanqin Peng; Sophia Rits-Volloch; Jianming Lu; Donghyun Park; Elise Zablowsky; Michael S Seaman; Bing Chen
Journal:  Science       Date:  2015-06-25       Impact factor: 47.728

8.  Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.

Authors:  Kristel L Emmer; Lindsay Wieczorek; Steven Tuyishime; Sebastian Molnar; Victoria R Polonis; Hildegund C J Ertl
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

9.  High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence.

Authors:  Yimeng Wang; Christopher Sundling; Richard Wilson; Sijy O'Dell; Yajing Chen; Kaifan Dai; Ganesh E Phad; Jiang Zhu; Yongli Xiao; John R Mascola; Gunilla B Karlsson Hedestam; Richard T Wyatt; Yuxing Li
Journal:  J Immunol       Date:  2016-03-21       Impact factor: 5.422

10.  Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies.

Authors:  M Anthony Moody; Isabela Pedroza-Pacheco; Nathan A Vandergrift; Cecilia Chui; Krissey E Lloyd; Robert Parks; Kelly A Soderberg; Ane T Ogbe; Myron S Cohen; Hua-Xin Liao; Feng Gao; Andrew J McMichael; David C Montefiori; Laurent Verkoczy; Garnett Kelsoe; Jinghe Huang; Patrick R Shea; Mark Connors; Persephone Borrow; Barton F Haynes
Journal:  Sci Immunol       Date:  2016-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.